E

Elicera Therapeutics AB
STO:ELIC

Watchlist Manager
Elicera Therapeutics AB
STO:ELIC
Watchlist
Price: 6.49 SEK -2.11% Market Closed
Market Cap: 315m SEK

Wall Street
Price Targets

ELIC Price Targets Summary
Elicera Therapeutics AB

Wall Street analysts forecast ELIC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ELIC is 8.67 SEK with a low forecast of 8.59 SEK and a high forecast of 8.93 SEK.

Lowest
Price Target
8.59 SEK
32% Upside
Average
Price Target
8.67 SEK
34% Upside
Highest
Price Target
8.93 SEK
38% Upside
Elicera Therapeutics AB Competitors:
Price Targets
ALDX
Aldeyra Therapeutics Inc
110% Upside
CUV
Clinuvel Pharmaceuticals Ltd
107% Upside
688366
Shanghai Haohai Biological Technology Co Ltd
49% Upside
OXB
Oxford BioMedica PLC
21% Upside
KURN
Kuros Biosciences AG
15% Upside
CSL
CSL Ltd
35% Upside
SKYE
Skye Bioscience Inc
641% Upside
086900
Medy Tox Inc
10% Upside

Revenue
Forecast

Revenue Estimate
Elicera Therapeutics AB

For the last 3 years the compound annual growth rate for Elicera Therapeutics AB's revenue is 2 182%. The projected CAGR for the next 3 years is 77%.

2 182%
Past Growth
77%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Elicera Therapeutics AB

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-11%
Average Miss

Net Income
Forecast

Net Income Estimate
Elicera Therapeutics AB

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-63%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ELIC's stock price target?
Price Target
8.67 SEK

According to Wall Street analysts, the average 1-year price target for ELIC is 8.67 SEK with a low forecast of 8.59 SEK and a high forecast of 8.93 SEK.

What is Elicera Therapeutics AB's Revenue forecast?
Projected CAGR
77%

For the last 3 years the compound annual growth rate for Elicera Therapeutics AB's revenue is 2 182%. The projected CAGR for the next 3 years is 77%.

Back to Top